Education
About Us
Working with TipRanks
Follow Us
Caribou Biosciences (CRBU)
NASDAQ:CRBU
CRBU Stock Chart & Stats
$1.71
-$0.16(-8.56%)
At close: 4:00 PM EST
$1.71
-$0.16(-8.56%)
Day’s Range― - ―
52-Week Range$0.66 - $3.54
Previous CloseN/A
Volume598.80K
Average Volume (3M)1.20M
Market Cap
$159.83M
Enterprise Value$174.15M
Total Cash (Recent Filing)$147.26M
Total Debt (Recent Filing)$25.46M
Price to Earnings (P/E)―
Beta2.27
Next Earnings
May 12, 2026EPS Estimate
-0.31Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.28
Shares Outstanding93,468,040
10 Day Avg. Volume1,354,975
30 Day Avg. Volume1,199,069
Financial Highlights & Ratios
PEG Ratio0.28
Price to Book (P/B)1.22
Price to Sales (P/S)0.00
P/FCF Ratio-1.32
Enterprise Value/Market Cap1.09
Enterprise Value/Revenue18.74
Enterprise Value/Gross Profit-8.21
Enterprise Value/Ebitda-1.24
Forecast
1Y Price Target
$7.75Price Target Upside353.22% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-1.34
Revenue Forecast (FY)$21.44M
Bulls Say, Bears Say
Bulls Say
Proprietary CRISPR Platform & Allogeneic FocusCaribou’s chRDNA-based gene‑editing platform and explicit focus on off‑the‑shelf allogeneic CAR‑T/CAR‑NK therapies provide a durable technological moat. If clinical and regulatory progress continues, the platform supports scalable manufacturing, faster patient access and differentiation versus autologous models.
Collaboration And Licensing Revenue ModelA business model anchored in collaborations and licensing supplies recurring non‑dilutive or semi‑dilutive funding to support R&D over multiple years. Strategic partnerships can share development risk, validate tech, and provide milestone liquidity that sustains operations while clinical programs advance.
Low Leverage Offers Financial FlexibilityRelatively low reported debt versus equity gives the company room to raise capital or secure financings without heavy interest burdens. This structural balance‑sheet flexibility supports continued clinical investment and partner negotiations even amid operational losses, reducing immediate solvency risk.
Bears Say
Persistent High Cash Burn And Negative FCFSustained large operating deficits and deeply negative free cash flow create structural financing risk. Over the medium term this necessitates frequent capital raises or partner funding, heightening dilution risk and potentially delaying trials or program advancement if markets tighten or partnerships slow.
Revenue Collapse And Top-line VolatilityA sharp decline to virtually no revenue undermines operating resilience and increases dependence on external financing or milestone receipts. Without steady commercial receipts, planning and runway visibility worsen, and the company’s ability to demonstrate sustained market traction is limited until clinical success yields product sales.
Large, Persistent Losses Eroding EquityMaterial recurring losses have significantly eroded the equity cushion, reducing resilience to negative shocks and constraining strategic flexibility. Over months, diminished equity increases reliance on external capital, raises dilution likelihood, and can limit long‑term investment in platforms if funding terms worsen.
Caribou Biosciences News
CRBU FAQ
What was Caribou Biosciences’s price range in the past 12 months?
Caribou Biosciences lowest stock price was $0.66 and its highest was $3.54 in the past 12 months.
What is Caribou Biosciences’s market cap?
Caribou Biosciences’s market cap is $159.83M.
When is Caribou Biosciences’s upcoming earnings report date?
Caribou Biosciences’s upcoming earnings report date is May 12, 2026 which is in 67 days.
How were Caribou Biosciences’s earnings last quarter?
Caribou Biosciences released its earnings results on Mar 05, 2026. The company reported -$0.28 earnings per share for the quarter, beating the consensus estimate of -$0.31 by $0.03.
Is Caribou Biosciences overvalued?
According to Wall Street analysts Caribou Biosciences’s price is currently Undervalued.
Does Caribou Biosciences pay dividends?
Caribou Biosciences does not currently pay dividends.
What is Caribou Biosciences’s EPS estimate?
Caribou Biosciences’s EPS estimate is -0.31.
How many shares outstanding does Caribou Biosciences have?
Caribou Biosciences has 93,468,040 shares outstanding.
What happened to Caribou Biosciences’s price movement after its last earnings report?
Caribou Biosciences reported an EPS of -$0.28 in its last earnings report, beating expectations of -$0.31. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Caribou Biosciences?
Currently, no hedge funds are holding shares in CRBU
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Caribou Biosciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.75 (353.22% Upside)
$7.75 (353.22% Upside)
Hedge Fund Trend
Decreased
By 21.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $18.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 0.2%
Last 30 Days ▲ 3.4%
Last 30 Days ▲ 3.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
41.00%
12-Months-Change
Fundamentals
Return on Equity
-74.28%
Trailing 12-Months
Asset Growth
-40.77%
Trailing 12-Months
Company Description
Caribou Biosciences
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy for the treatment of relapsed or refractory multiple myeloma. The company also develops CB-012, an allogeneic anti-CD371 CAR-T cell therapy for the treatment of relapsed or refractory acute myeloid leukemia; and CB-020, an allogeneic CAR-NK cell therapy for the treatment of solid tumors. It has collaboration with AbbVie Manufacturing Management Unlimited Company to develop CAR-T cell therapies. The company was incorporated in 2011 and is headquartered in Berkeley, California.
CRBU Stock 12 Month Forecast
Average Price Target
$7.75
▲(353.22% Upside)
Technical Analysis
Sangamo Biosciences
―
Cellectis SA
―
Cabaletta Bio
―
Elicio Therapeutics
―
Vor Biopharma
―
Ownership Overview
7.98% Insiders
6.34% Mutual Funds
8.33% Other Institutional Investors
69.55% Public Companies and
Individual Investors